Heron Therapeutics, Inc. - Common Stock (HRTX)

Heron Therapeutics reported mixed Q3 2025 results, missing revenue and earnings estimates. Despite strong growth from its Acute Care products, the miss led to a negative market reaction.

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

HRTX stock results show that Heron Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

HRTX stock results show that Heron Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Heron Therapeutics' Q4 2023 results: Beat EPS consensus at $(0.07), $34.23 million sales, up 14% Y/Y. Strong momentum in acute and oncology care franchises. Fiscal year 2024 guidance: $138 million-$158 million revenue, with positive adjusted EBITDA.

Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24 insurance revenue guidance.

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.